Literature DB >> 8230285

Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells.

A F Sobrero1, C Aschele, A P Guglielmi, A M Mori, G G Melioli, R Rosso, J R Bertino.   

Abstract

BACKGROUND: Our recent findings in vitro in the human colon adenocarcinoma cell line HCT-8 suggest that resistance to fluorouracil (5-FU) in patients with advanced colorectal cancer might be overcome by use of a different treatment schedule.
PURPOSE: We tested the hypothesis that HCT-8 cells resistant to short-term 5-FU exposure retain sensitivity to continuous exposure and studied interactions between the two schedules.
METHODS: HCT-8 cell lines resistant to short-term (pulse) treatment with 5-FU or to continuous exposure were obtained by six exposures to different concentrations of 5-FU for 4 hours or 7 days. We used a monolayer clonogenic assay to determine 5-FU-induced cell kill in resistant HCT-8 cells and sensitive parent cells. Parent cells were exposed to different concentrations of 5-FU for 1, 4, or 24 hours (short term), for 7 days (continuous exposure), or in a combination of both types of schedules. In a study of the mechanism of interaction between short-term and continuous exposure in parent cells, we performed flow cytometric DNA analysis to determine the percentage of cells in S phase and assays of thymidylate synthase inhibition in intact cells and of incorporation of [6-3H)]5-FU nucleotides into nucleic acids.
RESULTS: Sensitive HCT-8 cells became fully resistant to 5-FU within five or six treatments, and low-dose continuous exposure almost immediately produced resistant clones. HCT-8 cells resistant to 5-FU given every 4 hours retained full sensitivity to continuous exposure, suggesting lack of cross-resistance between the two schedules, but cells resistant to continuous exposure were cross-resistant to short-term treatment. Parent cells showed a statistically significant (synergistic) enhancement of the cytotoxic activity for 5-FU exposure for 1 hour (100, 300, or 500 microM) followed by continuous exposure (0.5, 1, or 2 microM) or 4 hours (10, 30, or 60 microM) followed by continuous exposure (1 or 2 microM). Short-term plus continuous exposure produced a marked increase in percentage of S-phase cells, compared with the percentage for each schedule alone. The combination of 1-hour exposure and continuous exposure (1000 and 2 microM, respectively) produced a marked accumulation of cells in S phase at 24 hours (59%), which lasted up to 96 hours (53%). The combination of the two schedules produced only additive enhancement of thymidylate synthase inhibition as well as incorporation of [6-3H]5-FU nucleotides into nucleic acids of HCT-8 cells.
CONCLUSIONS: Our findings provide a rationale for the use of bolus 5-FU and continuous infusion 5-FU in sequence. IMPLICATION: We are conducting a clinical trial of bolus methotrexate followed by continuous-infusion 5-FU plus leucovorin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8230285     DOI: 10.1093/jnci/85.23.1937

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  12 in total

Review 1.  How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.

Authors:  P Ragnhammar; H Blomgren
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

Review 2.  5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.

Authors:  J L Grem
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

Review 3.  Should we still be using bolus 5-FU prior to infusional regimens in gastrointestinal cancers? A practical review.

Authors:  Larissa Costa Amorim; Renata D'Alpino Peixoto
Journal:  Int Cancer Conf J       Date:  2021-11-24

4.  Multicentre phase II study of leucovorin plus pharmacokinetic modulating chemotherapy for metastatic colorectal cancer.

Authors:  Yasuhiro Inoue; Koji Tanaka; Junichiro Hiro; Yuji Toiyama; Chikao Miki; Masato Kusunoki
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

5.  A phase II study of leucovorin, 5-FU and docetaxel combination chemotherapy in patients with inoperable or postoperative relapsed gastric cancer.

Authors:  Kwang-Sun Lee; Ha-Yeon Lee; Eun-Kyung Park; Joung-Soon Jang; Sang-Jae Lee
Journal:  Cancer Res Treat       Date:  2008-03-31       Impact factor: 4.679

6.  Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study.

Authors:  C Aschele; A Guglielmi; G L Frassineti; C Milandri; D Amadori; R Labianca; M Vinci; L Tixi; C Caroti; E Ciferri; E Verdi; R Rosso; A Sobrero
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

7.  5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.

Authors:  A Sobrero; A Guglielmi; M Cirillo; E Recaldin; G L Frassineti; C Aschele; A Ravaioli; P Testore; C Caroti; L Gallo; M A Pessi; E Cortesi; D Turci; F Grossi; R Labianca
Journal:  Br J Cancer       Date:  2001-04-20       Impact factor: 7.640

8.  Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results.

Authors:  Alessandro Passardi; Francesca Fanini; Livia Turci; Flavia Foca; Paola Rosetti; Silvia Ruscelli; Andrea Casadei Gardini; Martina Valgiusti; Claudio Dazzi; Maurizio Marangolo
Journal:  Oncologist       Date:  2017-06-07

9.  Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.

Authors:  A V Patterson; H Zhang; A Moghaddam; R Bicknell; D C Talbot; I J Stratford; A L Harris
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

10.  Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil.

Authors:  A Guglielmi; S Barni; A Zaniboni; N Pella; O Belvedere; G D Beretta; F Grossi; L Frontini; F Puglisi; R Labianca; A Sobrero
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.